madman
Super Moderator
Ashley E. Ross, MD, PhD, discusses the novel nomograms he and his team at Northwestern Medicine developed. The nomograms incorporate multiparametric prostate MRI, serum biomarkers and patient clinicodemographic features to help clinicians risk stratify patients with elevated PSA of 2–20 ng/mL who are being considered for biopsy.
The nomograms were internally validated and evaluated in an independent cohort of men. The accuracy of the nomograms was high, with areas under the curves (AUC) of ≥0.885 in the training cohort and ≥0.896 in the independent validation cohort.
